<SEC-DOCUMENT>0001193125-26-008907.txt : 20260109
<SEC-HEADER>0001193125-26-008907.hdr.sgml : 20260109
<ACCEPTANCE-DATETIME>20260109160523
ACCESSION NUMBER:		0001193125-26-008907
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260109
DATE AS OF CHANGE:		20260109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39926
		FILM NUMBER:		26523089

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d69982d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tern="http://www.ternspharma.com/20260107" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-272">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-01-07_to_2026-01-07">0001831363</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="tern-20260107.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-01-07_to_2026-01-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001831363</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-07</xbrli:startDate> <xbrli:endDate>2026-01-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-283">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt:datemonthdayyearen" id="ixv-284">January 07, 2026</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-285">Terns Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:stateprovnameen" id="ixv-286">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-287">001-39926</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-288">98-1448275</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-289">1065 East Hillsdale Blvd.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-290">Suite 100</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-291">Foster City</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:stateprovnameen" id="ixv-292">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-293">94404</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-294">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-295">525-5535</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:boolballotbox" id="ixv-296">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:boolballotbox" id="ixv-297">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:boolballotbox" id="ixv-298">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:boolballotbox" id="ixv-299">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><br/>Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-300">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-301">TERN</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:exchnameen" id="ixv-302">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:boolballotbox" id="ixv-303">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2026-01-07_to_2026-01-07" format="ixt-sec:boolballotbox" id="ixv-304">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2026, Terns Pharmaceuticals, Inc. (the Company) issued a press release regarding the Company&#8217;s 2026 priorities and program milestones to be discussed at a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The press release also included an update regarding the Company&#8217;s unaudited cash, cash equivalents and marketable securities for the year ended December&#160;31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Item 2.02 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border-spacing:0;margin-left:auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d69982dex991.htm">Press Release issued by Terns Pharmaceuticals, Inc. on January&#160;7, 2026.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table></div> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">TERNS PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;9, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Caryn McDowell</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Caryn McDowell</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Legal Officer and Corporate Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d69982dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1%">


<IMG SRC="g69982g0109030931336.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare
Conference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 7, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>CARDINAL
Phase 1/2 trial of <FONT STYLE="white-space:nowrap">TERN-701</FONT> enrolling well, with multiple important milestones in 2026 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Planned milestones include pivotal dose selection, EOP2 regulatory interaction in <FONT STYLE="white-space:nowrap">mid-2026,</FONT> updated
and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">TERN-701</FONT> was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Year-end</FONT> 2025 unaudited cash, cash equivalents and marketable securities of approximately
$1.0&nbsp;billion, expected to provide runway into 2031 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Terns Pharmaceuticals, Inc.
(&#8220;Terns&#8221; or the &#8220;Company&#8221;) (Nasdaq: TERN), a clinical-stage oncology company, today announced that management will provide an update on 2026 priorities and program milestones during the Company&#8217;s presentation at the 44<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Annual J.P. Morgan Healthcare Conference on January&nbsp;12<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>, 2026 at 3:45pm in San Francisco, CA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Last year was transformative for Terns as we completed our transition to an oncology company anchored by our allosteric
<FONT STYLE="white-space:nowrap">BCR-ABL</FONT> inhibitor, <FONT STYLE="white-space:nowrap">TERN-701,</FONT> for CML. Following compelling <FONT STYLE="white-space:nowrap">TERN-701</FONT> data at ASH in December, and our subsequent capital raise, we
are in a strong position to advance <FONT STYLE="white-space:nowrap">TERN-701</FONT> towards pivotal trial initiation. Based on accelerating momentum in our CARDINAL trial, our goal for pivotal trials is to enroll patients more quickly than
historical precedents in CML and to generate data that further strengthen the position of <FONT STYLE="white-space:nowrap">TERN-701</FONT> as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-disease</FONT></FONT>
therapy across all lines of CML treatment,&#8221; said Amy Burroughs, chief executive officer of Terns. &#8220;We believe that reaffirming clinical differentiation and advancing to product launch rapidly will be key factors to maximize the
therapeutic and commercial potential of <FONT STYLE="white-space:nowrap">TERN-701,&#8221;</FONT> added Ms.&nbsp;Burroughs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anticipated 2026 Priorities
and Key Milestones </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">TERN-701:</FONT> Oral, allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> tyrosine
kinase inhibitor (TKI) for chronic myeloid leukemia (CML) </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anticipated 2026 milestones for <FONT STYLE="white-space:nowrap">TERN-701</FONT> include: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selection of pivotal dose in mid-2026 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">End of Phase 2 regulatory interaction with U.S. FDA in mid-2026 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Updated and expanded CARDINAL data by second half of 2026 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of first pivotal trial (2L+ population) in late 2026 / early 2027 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preliminary study design anticipates evaluation of <FONT STYLE="white-space:nowrap">TERN-701</FONT> vs control
arm of investigator&#8217;s choice 2 <SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> generation TKI (dasatinib, nilotinib, bosutinib) with major molecular response (MMR) at six months as the primary endpoint </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New cohort added to the ongoing CARDINAL Phase 1/2 study to evaluate
<FONT STYLE="white-space:nowrap">TERN-701</FONT> 500mg QD in approximately 20 patients with <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> resistance mutations including T315I, M244V, F359I/C/V and others </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At the 67<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> ASH Annual Meeting in December 2025, Elias
Jabbour, MD, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, presented unprecedented safety and efficacy data from the CARDINAL trial </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CARDINAL enrolled a predominantly 3L+ patient population with 38% of patients having received prior asciminib of
whom 75% discontinued due to lack of efficacy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">TERN-701</FONT> showed an encouraging safety profile (N=63)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">87% (55/63) of patients remained on treatment as of the data cutoff </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No dose-limiting toxicities were observed in dose escalation, and a maximum tolerated dose was not reached
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The majority of treatment-emergent adverse events (TEAEs) were low grade with no apparent dose relationship
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grade 3 or higher TEAEs were all less than 10%, most commonly neutropenia (8%) and thrombocytopenia (8%)
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unprecedented efficacy with MMR achievement rate by 24 weeks of 75% (18/24) in evaluable patients enrolled at the
recommended phase 2 dose range of <U>&gt;</U>320mg QD, trending <FONT STYLE="white-space:nowrap">2-3X</FONT> higher than asciminib in Phase 1 and Phase 3 studies evaluating a 3L+ patient population </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deep molecular response (DMR) achievement rate by 24 weeks of 36% (10/28) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Encouraging MMR rates in patients with prior asciminib (n=10) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overall MMR rate of 60% (6/10), with 43% (3/7) achieving MMR and 100% (3/3) maintaining MMR
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enrollment has accelerated with 85+ patients enrolled as of December&nbsp;8, 2025 <U> </U></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other Pipeline Programs </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discovery efforts are underway on undisclosed targets for oncology indications </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Terns is seeking a strategic partner to advance the <FONT STYLE="white-space:nowrap">TERN-501</FONT> and <FONT
STYLE="white-space:nowrap">TERN-801</FONT> legacy metabolic programs </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Updates </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2025, Terns completed an upsized public offering of 18,687,500 shares of its common stock, generating
gross proceeds of approximately $747.5&nbsp;million before deducting underwriting discounts and commissions and other offering expenses </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unaudited cash, cash equivalents and marketable securities for the year ended December&nbsp;31, 2025, of
approximately $1.0&nbsp;billion expected to provide cash runway into 2031, including the first potential approval and launch of <FONT STYLE="white-space:nowrap">TERN-701</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A live webcast of the Company&#8217;s J.P. Morgan Healthcare Conference presentation will be available on the investor relations page of Terns&#8217; website
at <U>http://ir.ternspharma.com</U>. A replay of the webcast will be archived on Terns&#8217; website for at least 30 days following the presentation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Terns Pharmaceuticals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals is a
clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program <FONT STYLE="white-space:nowrap">TERN-701</FONT> is a highly selective, allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> inhibitor
with a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-disease</FONT></FONT> profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more
information, please visit: <U>www.ternspharma.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or
&#8220;our&#8221;) within the meaning of the federal securities laws, including those related to the Company&#8217;s expectations of timing and potential results of the clinical trials and other development activities of the Company and its
partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company&#8217;s small-molecule product candidates; the potential for the mechanisms of action of the
Company&#8217;s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company&#8217;s product candidates in their targeted indications, including the clinical utility of the data from
and the endpoints used in the Company&#8217;s clinical trials; the Company&#8217;s clinical development plans and activities; the Company&#8217;s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety,
metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company&#8217;s plans for and ability to continue to execute on its current development strategy, including
potential combinations involving multiple product candidates; and the Company&#8217;s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press
release, including statements regarding the Company&#8217;s strategy, future financial condition, future operations, future trial results, future approvals, future launches, projected costs, prospects, plans, objectives of management and expected
market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221;
&#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and
financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#8217;s plans to vary materially, including the risks
associated with the initiation, cost, timing, progress, results and utility of the Company&#8217;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed
discussion of the risk factors that could affect the Company&#8217;s actual results, please refer to the risk factors identified in the Company&#8217;s SEC reports, including but not limited to its Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024 and its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended March&nbsp;31, 2025, June&nbsp;30, 2025 and September&nbsp;30, 2025.
Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts for Terns </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justin Ng </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@ternspharma.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jenna Urban </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Berry&nbsp;&amp; Company Public Relations <U>
</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@ternspharma.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tern-20260107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/10/2026 1:41:23 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:tern="http://www.ternspharma.com/20260107"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.ternspharma.com/20260107"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20260107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20260107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tern-20260107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/10/2026 1:41:23 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tern-20260107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/10/2026 1:41:23 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tern-20260107.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g69982g0109030931336.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69982g0109030931336.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  S /,# 2(  A$! Q$!_\0
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7>^KUTZGC8*$/:-V/H?)HHHK\^/</_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 07, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  07,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Terns Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1065 East Hillsdale Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">525-5535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TERN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d69982d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d69982d8k.htm">d69982d8k.htm</File>
    <File>tern-20260107.xsd</File>
    <File>tern-20260107_lab.xml</File>
    <File>tern-20260107_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d69982d8k.htm": {
   "nsprefix": "tern",
   "nsuri": "http://www.ternspharma.com/20260107",
   "dts": {
    "inline": {
     "local": [
      "d69982d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "tern-20260107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tern-20260107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tern-20260107_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-01-07_to_2026-01-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d69982d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-01-07_to_2026-01-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d69982d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ternspharma.com//20260107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-26-008907-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-008907-xbrl.zip
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M5NI]!;8E(5JZ 2X-,^!V6%_7)"AC^])CF+(2H>,\N;J,9U'/.S_=+ES+!2O
M?I3?XW_TL[W)9X'H8Q@BQ)(0*L#Y3"3F$V;#S[@=>J)TK,@"LNGZD_N?*V9:
M,9/-MI_-"K/L-2FM0!4S\ N?Q6D7,:WPMC8R'A@MS;WJSMYN=;O18&8 0I\L
M&9D8%XB&K5#>0S7/38[ZY5*?+IX#8WA"^/.U4MC?=K=VZ]N67*$MEL)LZ)CY
M J^!X]!6MVA[6DCY-6E6D@5'EL:0)LDS+B>3QK(KD1'/X,@57_QU^>+^QXO_
M9(60J(J)#1=/F_:M9M7Q&F:)S8!_MD[0PC)!-)O96D'50@8RCN^NSN0U#FB@
M(?X 4W>5%'[D0L/+/)%7*0YSQ *L,C$270_KP[@$D]EB/$]7S9DJUY-5C^!#
M+@/:1&7K>=CK&4I/3FOI%"LO;N$&Q.D8B:GI/$$W;9 D\?[&AM3U!-^*J292
M':01.DMU=@3=Q0$?9[//%I-/0WL#2B7$^QL+AB%<P4B!P*]:#>;S,8(M*R!C
M+V9,UK>\9L^KU9_HJC197 7JCZ@UL7A@L UYN?1$X2C8#F"ZOHWL/ #80<M(
M^P8PE"\0<?;D%>OE<2\!J\YF.9LZNTHU;L2D7-3+:P%@W1?L/1AG->V&XC^J
M@)$7O"B7*-90*"L#8_SDPC)Y3B%5>0%M'(!X%!R)VTMQ?* A2!]P"F/'9=F9
M7;68Z.TIX+U(VA)76&!&&IL/E*5AF&+M)$VU?<HE&;D:49@-%".#"(8YZLD^
M\N5H-%K,D7] >983GN*L\++4)6P&NP'_0).$AMEC@:3:N5+DQ-P"UPJ[PD4V
M^JLSSD#:ZF68QV<IABG*',P!I#!-+7!3,Y.I\<?9W19]8VOSQ=WR2D*N>21F
M6U)3G92'*Y=<JTIU7A<.$2TM<!RL,CG:$SY&>XL:.. C,ZT-\]R;R>VC6>UA
M]:R3]]BWI")%5!,NUZ% L#1(\A3'O(*1*T U,3=],12!BFU*)/)V7ABP,+:M
M(9F8<LFYK>; %93*QBM&16#>H"9L\,36,"MV12R/AK<)@=]K[@A/Y*63/!A+
MD@]HQRB619JJ@[2(-L_L<])/9@.%PAO ;IG0VOEY40LZ4)\OIC?;;;;FPER+
MP2-HEWI"D0*Q9N<#GP;2R1@2V0C\1Q:[8!H6>8^,-6MWY:#(!BWFP^+=%5N8
MB62@NT!I6&IL<N.B"<V@[&#Y2T7D@;WAG* )!A=_/H5^G4LI:U18R>X<NWGR
M% DPD>HV#[-+),AD?+5<FH1&0*QT"[MBI0E*')'8P F-.LU_<Y7"K*?*M>5K
MRWMNA@8SIQZ#ZMRF$Z7(Q$)JN8E!E]G%#;J,2/7.R$XD%S?5-K.O0'$7B1H7
M: +<G<\?)MN547YA<*@".G?**_,NFFX&EJ5;1NQO]PUG2M,K. G8ATEQ;U"W
MCG,GG5X1!B2MAV;-$9BB!6EOR4DY*,76'BO4S\.Z:R;3'1F&,]V"23.D7(H0
M*70U#;0YJ9/3LI<FJ4:/)L*:<$1'H(_5]^Z9BMWE9Y,WV5MA3F3GK9D;-&FQ
MOA#B&)Y\L\Z6!U:8;3!(9?P1$0(N6_>;M=6($(4RHZX0!GT.,"?7D/6U&B7@
M/J(?\KA:K8/J9$:%Y-CA/,8J10@PB?E-LC=>II)1#P@LJ&=M5Y."6P=LX70H
ME^&LLIW<;9][8DP:SK6Z^GVSS;CE(HR#0C^YYLZ89OX;L MG&^V5^[G6^:_Q
MSGRX8-J6ZK.M6"1RM@TKWT1S$PCYG(F2[_+L T3!W'*S I!BKNN<\^<>:'0F
MYB:-(>VYML$BJEE--&=:@3,YUX:?9VT3"\6 ?8,I/D ]9%5K8J#QCEAUT\ML
M(1"+3N&!VG9<X]*?L<.<WX"XR")6]T? W*XX)/X.%ACBE*2RG8&5W.1Y%Q!<
MISNDF5F#IZA=*A1JNUC"" %2)!C/2N>BF*RR#$/(_> [H >>U_W])MR*K94[
MMTY8>BZ [%HMP622U;@T(!! V(*.\A*:Q$*)53 BBU*KFV+]0C.1>Y:V>0\1
MADM)5-B:^\ZL0.:1J'1AK5@ 6:,@)F/3FA-+B69%C468NR8!%$0?#1:[Q TP
MLPB9(A9M(=9J+WP!#TU*7(7Z24OS8.D^/>6"]^CQU-C#&] P:<'VSO2AQ AU
MF(=S'K/F2+'#D$-TPG#K-3G$LU8;S0@L,V,44#L_L+?QH*PB397T0M7Y!M7<
ME*Q.36[&[INSU!PP"YR#81N,_U#;(ZZ#!:G([;PLZ9/<YFD+,:._HS(,@%LK
MO@^ I,B1UG?F,!(0/D!UA1'TU)@"'?';25'5R;8X<"]:V/0^Y9ZX%CU[(#?7
MK5-O\G'3][9S@F$S/%(N;E@7V!.71/>%1&[QN!OO-_0!R@%89OB<8[QFH_9K
ML3;S<\*W6YGWQGY+P7L36'-HX<C+Q_UM=ER0"%+YQ@U]@;"8#1M_3B/AVAHN
M303G<BOBI#A/]ZQ>+G6^>_ ,V59C#-N5P 8WN3KE0]*A2L(?!%Z9 DLGP!(U
MKA"TJYINCX "E$U+K1)K26.0C9M"+/)/>Z'@I_T5-O88%X2<YZAJ@R]_1(P(
M1CYSH?"G@KFOLM+/*)TB=ME?%KE^'9K>M[,@O_F_F=C@HMRF5S_0 -)BS0S^
MU#Z^#EU%%'%VK[L\6A+S?)6ACH7._D:"MSR,#W+1<FV/CF_R$Q78 I0'RTC]
M6EN-<7L^N\TX]!*I!/MR=?H[--+?F/5O4$L#!!0    ( *J *5Q]@8XM/P,
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M.3@R9#AK+FAT;5!+ 0(4 Q0    ( *J *5QWC)5YAA0  #AK   0
M      "  2$0  !D-CDY.#)D97@Y.3$N:'1M4$L! A0#%     @ JH I7'V!
MCBT_ P  4PL  !$              ( !U20  '1E<FXM,C R-C Q,#<N>'-D
M4$L! A0#%     @ JH I7,SWF:.K!@  HDD  !4              ( !0R@
M '1E<FXM,C R-C Q,#=?;&%B+GAM;%!+ 0(4 Q0    ( *J *5Q9!];VW00
M  ,N   5              "  2$O  !T97)N+3(P,C8P,3 W7W!R92YX;6Q0
52P4&      4 !0 ^ 0  ,30

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d69982d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tern-20260107.xsd" xlink:type="simple"/>
    <context id="duration_2026-01-07_to_2026-01-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831363</identifier>
        </entity>
        <period>
            <startDate>2026-01-07</startDate>
            <endDate>2026-01-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-272">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-01-07_to_2026-01-07"
      id="Hidden_dei_EntityCentralIndexKey">0001831363</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-283">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-284">2026-01-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-285">Terns Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-286">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-287">001-39926</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-288">98-1448275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-289">1065 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-290">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-291">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-292">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-293">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-294">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-295">525-5535</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-296">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-297">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-298">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-299">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-300">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-301">TERN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-302">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-303">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2026-01-07_to_2026-01-07" id="ixv-304">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
